Lepu Biopharma Co., Ltd. (HKG:2157)

Revenue by Product

Financials in millions HKD. Fiscal year is January - December.

Year Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Pharmaceutical Products	325.63M	Log In	Log In
Pharmaceutical Products Growth	190.66%	Log In	Log In
Contract Development and Manufacturing Organisations Services	49.33M	Log In	Log In
Licensing Income	23.81M	Log In	Log In
Licensing Income Growth	-82.62%	Log In	Log In
Drugs for Cancer Targeted Therapy and Immunotherapy	-	Log In	Log In

Revenue by Geography

Financials in millions HKD. Fiscal year is January - December.

Year Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
China	374.96M	Log In	Log In
China Growth	234.69%	Log In	Log In
Overseas	23.81M	Log In	Log In
Overseas Growth	-82.62%	Log In	Log In